Eliso Solomko Selected Research

alofanib

1/2017	Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies.
1/2016	Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eliso Solomko Research Topics

Disease

3	Neoplasms (Cancer) 01/2021 - 01/2016
2	Ovarian Neoplasms (Ovarian Cancer) 01/2017 - 01/2016
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2021
1	Necrosis 01/2017
1	Ovarian Epithelial Carcinoma 01/2017
1	Triple Negative Breast Neoplasms 01/2016
1	Melanoma (Melanoma, Malignant) 01/2016

Drug/Important Bio-Agent (IBA)

2	alofanibIBA 01/2017 - 01/2016
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2021
1	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 01/2021
1	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 01/2021
1	PlatinumIBA 01/2017
1	Cytotoxins (Cytolysins)IBA 01/2017
1	Carboplatin (JM8)FDA LinkGeneric 01/2017
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2017
1	Proteins (Proteins, Gene)FDA Link 01/2017
1	Protein Isoforms (Isoforms)IBA 01/2016

Therapy/Procedure

1	Heterologous Transplantation (Xenotransplantation) 01/2017
1	Drug Therapy (Chemotherapy) 01/2017